COVID-19 Vaccination and Estimated Public Health Impact in California

Key Points Question How many COVID-19 cases, hospitalizations, and deaths were averted because of COVID-19 vaccination in California? Findings In this modeling study using data from the California Department of Public Health, COVID-19 vaccination was estimated to have prevented more than 1.5 million COVID-19 cases, 72 000 hospitalizations, and 19 000 deaths during the first 10 months of vaccination, through October 16, 2021. Meaning These findings suggest that COVID-19 vaccination had a large public health benefit in California, which can be generalized across the United States.

[1]  A. Charlett,et al.  Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection , 2022, The New England journal of medicine.

[2]  D. Zeng,et al.  Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina , 2022, The New England journal of medicine.

[3]  N. Andrews,et al.  Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines , 2022, The New England journal of medicine.

[4]  M. Drummond,et al.  Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: Updated reporting guidance for health economic evaluations , 2022, BMJ.

[5]  L. Abu-Raddad,et al.  Efficacy of Natural Immunity against SARS-CoV-2 Reinfection with the Beta Variant , 2021, The New England journal of medicine.

[6]  Manish M Patel,et al.  Effectiveness of Pfizer-BioNTech mRNA Vaccination Against COVID-19 Hospitalization Among Persons Aged 12–18 Years — United States, June–September 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[7]  K. Bruxvoort,et al.  Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study , 2021, BMJ.

[8]  O. A. Ogun,et al.  Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study , 2021, The Lancet.

[9]  David W. McDonald,et al.  Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[10]  K. Natarajan,et al.  Interim Estimates of COVID-19 Vaccine Effectiveness Against COVID-19–Associated Emergency Department or Urgent Care Clinic Encounters and Hospitalizations Among Adults During SARS-CoV-2 B.1.617.2 (Delta) Variant Predominance — Nine States, June–August 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[11]  J. Duchin,et al.  Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[12]  E. Klein,et al.  Infection with the SARS-CoV-2 Delta Variant is Associated with Higher Infectious Virus Loads Compared to the Alpha Variant in both Unvaccinated and Vaccinated Individuals , 2021, medRxiv.

[13]  W. Schaffner,et al.  Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years — COVID-NET, 13 States, February–April 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[14]  A. Galvani,et al.  Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis , 2021, Proceedings of the National Academy of Sciences.

[15]  R. Myers,et al.  Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant , 2021, The New England journal of medicine.

[16]  James C. Crosby,et al.  Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel — 33 U.S. Sites, January–March 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[17]  L. Abu-Raddad,et al.  Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants , 2021, The New England journal of medicine.

[18]  H. Fennema,et al.  Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 , 2021, The New England journal of medicine.

[19]  Matthew M. Cole,et al.  COVID-19 Vaccine Second-Dose Completion and Interval Between First and Second Doses Among Vaccinated Persons — United States, December 14, 2020−February 14, 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[20]  J. Brooks,et al.  Effectiveness of Mask Wearing to Control Community Spread of SARS-CoV-2. , 2021, JAMA.

[21]  J. Anesi.  The advisory Committee on Immunization practices’ updated interim recommendation for allocation of COVID-19 vaccine—United states, December 2020 , 2021, American Journal of Transplantation.

[22]  S. Moore,et al.  Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a modelling study , 2021, The Lancet.

[23]  B. Bell,et al.  The Advisory Committee on Immunization Practices’ Updated Interim Recommendation for Allocation of COVID-19 Vaccine — United States, December 2020 , 2021, MMWR. Morbidity and mortality weekly report.

[24]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[25]  J. Gargano,et al.  The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine — United States, December 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[26]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[27]  Laura Matrajt,et al.  Evaluating the Effectiveness of Social Distancing Interventions to Delay or Flatten the Epidemic Curve of Coronavirus Disease , 2020, Emerging infectious diseases.

[28]  N. Crepaz,et al.  Higher incidence of clear cell adenocarcinoma of the cervix and vagina among women born between 1947 and 1971 in the United States , 2011, Cancer Causes & Control.

[29]  G. Adler-Karlsson.  An alternative model. , 1987, Social science & medicine.